MedTrace Logo

A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers

NCT01281579 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2012-11-30

No results posted yet for this study

Summary

The purpose of this study is to determine blood and urine concentrations of canagliflozin and glucose in healthy adult volunteers after administration of single and multiple doses of canagliflozin.

Conditions

  • Healthy

Interventions

DRUG

Canagliflozin 100 mg

Tablets, oral, 100-mg, once daily on Day 1 and on Days 4 through 9.

DRUG

Canagliflozin 50 mg

Tablets, oral, 50-mg, once daily on Day 1 and on Days 4 through 9.

DRUG

Canagliflozin 300 mg

Tablets, oral, 300-mg, once daily on Day 1 and on Days 4 through 9.

Sponsors & Collaborators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-04-30
Completion
2011-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01281579 on ClinicalTrials.gov